Oftalmol Zh.2010;6:20-30.



(Седьмое издание, 2010 год)



1.Al Jamal RT, Kivela T. KI-67 immunopositivity in choroidal and ciliary body melanoma with respect to nucleolar diameter and other prognostic factors. Curr Eye Res. 2006;31:57- 67.

2.All-Ericsson C, Girnita L, Seregard S, et al. Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target. Invest Ophthalmol Vis Sci. 2002;43:l-8.

3.Blanco G. Diagnosis and treatment of orbital invasion in uveal melanoma. Can J Ophthalmol. 2004;39:388- 96.

4.Blom DJ, Luyten GP, Mooy C, et al. Human leukocyte antigen class I expression. Marker of poor prognosis in uveal melanoma. Invest Ophthalmol Vis Sci. 1997;38:1865- 72.

5.The Collaborative Ocular Melanoma Study Group. Accuracy of diagnosis of choroidal melanomas in the Collaborative Ocular Melanoma Study. COMS report no. 1. Arch Ophthalmol. 1990;108:1268- 73.

6.The Collaborative Ocular Melanoma Study Group. Comparison of clinical, echographic, and histopathological mea-surements from eyes with medium-sized choroidal melanoma in the collaborative ocular melanoma study: COMS report no. 21. Arch Ophthalmol. 2003:121:1163- 71.

7.The Collaborative Ocular Melanoma Study Group. Factors predictive of growth and treatment of small choroidal melanoma: COMS report no. 5. Arch Ophthalmol. 1997a;115: 1537- 44.

8.The Collaborative Ocular Melanoma Study Group. Mortality in patients with small choroidal melanoma. COMS report no. 4. Arch Ophthalmol. 1997b;l 15:886- 93.

9.The Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report no. 28. Arch Ophthalmol. 2006:124:1684- 93.

10.Damato B, Duke C, Coupland SE, et al. Cytogenetics of uveal melanoma: a 7-year clinical experience. Ophthalmology. 2007;! 14:1925- 31.

11.Diener-West M, Reynolds SM, Agugliaro DJ, et al. Development of metastatic disease after enrollment in the

COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group report no. 26. Arch Ophthalmol. 2005; 123: 1639- 43.

12.Durie FH, Campbell AM, Lee WR, Damato BE. Analysis of lymphocytic infiltration in uveal melanoma. Invest Ophthalmol Vis Sci. 1990;31:2106-10.

13.Eskelin S, Pyrhonen S, Summanen P, et al. Screening for metastatic malignant melanoma of the uvea revisited. Cancer. 1999;85:1151-9.

14.Eskelin S, Pyrhonen S, Hahka-Kemppinen M, et al. A prognostic model and staging for metastatic uveal melanoma. Cancer. 2003;97:465- 75.

15.Finger PT, Kurli M, Reddy S, et al. Whole body PET/CT for initial staging of choroidal melanoma. Br J Ophthalmol. 2005a;89(10):1270- 4.

16.Finger PT, Latkany P, Kurli M, lacob C. The Finger iridectomy technique: small incision biopsy of anterior segment tumors. Br J Ophthalmol. 2005b;89:946-9.

17.Finger PT, Chin K, lacob CE. 18-Fluorine-labelled 2-de-oxy-2-fluoro-D-glucose positron emission tomography/ computed tomography standardised uptake values: a non-invasive bio-marker for the risk of metastasis from choroidal melanoma. Br J Ophthalmol. 2006;90:1263-6.

18.Folberg R, Rummelt V, Parys-Van Ginderdeuren R, et al. The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology. 1993;100:1389- 98.

19.Foss AJ, Alexander RA, Jefferies LW, et al. Microvessel count predicts survival in uveal melanoma. Cancer Res. 1996;56:2900-3.

20.Hawkins BS. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24. Am J Ophthalmol. 2004; 138:936-51.

21.Hughes S, Damato BE, Giddings I, et al. Microarray comparative genomic hybridisation analysis of intraocular uveal melanomas identifies distinctive imbalances associated with loss of chromosome 3. Br J Cancer. 2005;93:1191-6.

22.Jager MJ, Hurks HM, Levitskaya J, Kiessling R. HLA ex-pression in uveal melanoma: there is no rule without some exception. Hum Immunol. 2002;63:444- 51.

23.Kivela T, Eskelin S, Kujala E. Metastatic uveal melanoma. Int Ophthalmol Clin. 2006;46:133- 49.

24.Kujala E, Makitie T, Kivela T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44:4651-9.

25.Kurli M, Reddy S, Tena LB, et al. Whole body positron emission tomography/computed tomography staging of metastatic choroidal melanoma. Am J Ophthalmol. 2005;104(2):193-9.

26.Makitie T, Summanen P, Tarkkanen A, Kivela T. Micro-vascular density in predicting survival of patients with choroidal and ciliary body melanoma. Invest Ophthalmol Vis Sci. 1999a;40:247i-80.

27.Makitie T, Summanen P, Tarkkanen A, Kivela T. Micro-vascular loops and networks as prognostic indicators in choroidal and ciliary body melanomas. J Natl Cancer Inst. 1999b;91:359-67.

28.Makitie T, Summanen P, Tarkkanen A, Kivela T. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2001;42:1414-21.

29.McLean IW, Zimmerman LE, Evans RM. Reappraisal of Callender's spindle a type of malignant melanoma of choroid and ciliary body. Am J Ophthalmol. 1978;86:557- 64.

30.McLean IW, Foster WD, Zimmerman LE, Gamel JW. Modifications of Callender's classification of uveal melanoma at the Armed Forces Institute of Pathology. Am J Ophthalmol. 1983;96:502- 9.

31.Mueller AJ, Freeman WR, Schaller UC, et al. Complex microcirculation patterns detected by confocal indocyanine green angiography predict time to growth of small choroidal melanocytic tumors: MuSIC Report II. Ophthalmology. 2002;109:2207-14.

32.Onken MD, Worley LA, Person E, et al. Loss of heterozygosity of chromosome 3 detected with single nucleotide polymorphisms is superior to monosomy 3 for predicting metastasis in uveal melanoma. Clin Cancer Res. 2007;13:2923-7.

33.Pach JM, Robertson DM, Taney BS, et al. Prognostic factors in choroidal and ciliary body melanomas with extras- cleral extension. Am J Ophthalmol. 1986;101:325-31.

34.Petrausch U, Martus P, Tonnies H, et al. Significance of gene expression analysis in uveal melanoma in comparison to standard risk factors for risk assessment of subsequent metastases. Eye. 2008;22:997- 1007.

35.Prescher G, Bornfeld N, Hirche H, et al. Prognostic implications of monosomy 3 in uveal melanoma. Lancet. 1996;347:1222- 5.

36.Reddy S, Kurli M, Tena LB, Finger PT. PET/CT imaging: detection of choroidal melanoma. Br J Ophthalmol. 2005;89(10):1270- 4.

37.Shields CL, Shields JA. Clinical features of small choroidal melanoma. Curr Opin Ophthalmol. 2002;13:135-41.

38.Tschentscher F, Husing J, Holler T, et al. Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res. 2003;63:2578- 84.

39.Worley LA, Onken MD, Person E, et al. Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma. Clin Cancer Res. 2007;13:1466-71.